Trading update

In brief · summary, not quotable

Abingdon Health plc announced a strong trading update for the financial year ended 30 June 2026, with total revenues expected to increase by 31% to £11.3 million, up from £8.6 million in FY25, driven by a 63% increase in second-half revenue primarily from Contract Development growth. The company achieved profitability at the adjusted EBITDA level in the second half of the year and ended the period with £2.9 million in cash, an increase from £1.9 million in the prior year. Abingdon Health is investing in its businesses to support future growth and anticipates further expansion in FY27.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your ABDX notes

York, UK and Madison, WI, USA, 29 July 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, provides a trading update for the financial year ended 30 June 2026 ("FY26").

Financial Highlights and Outlook

Strong growth in H2 and total revenue (including grant-funded income) for FY26 expected to be up 31% to £11.3m (FY25: £8.6m)
Good commercial progress in a strong H2, despite £0.5m reader unit sales scheduled for H2 moving to August at the customer's request
63% increase in H2 revenue compared to H1
H2 performance driven by significant growth in Contract Development (R&D) revenues
Company progressed to profitability at adjusted EBITDA* level in H2
Continued investment in Group businesses in FY26, including Abingdon Analytical and build-out of manufacturing capability at Abingdon Health USA, both of which will support future growth.
Cash of £2.9m (30 June 2025: £1.9m)
Board are confident of further growth in FY27, based on significant programmes previously announced and underway, with a further update to be provided on release of the Group's results for FY26.

The financial update above is provided subject to finalisation of the Group's results for FY26 which are expected to be published in early October 2026. Notice of results will be provided in due course.

*Adjusted EBITDA defined as operating profit/loss prior to the impact of depreciation, amortisation, share-based payment charges and certain non-recurring items.

Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented: "We are delighted to announce revenue growth of over 30% and a move into adjusted EBITDA profitability in the second half of the year. The CDMO contracts announced during the previous financial year provide a strong foundation for significant revenue growth in FY27. Abingdon Health is well-positioned to build on this momentum through our integrated, end-to-end service offering and our growing international footprint, particularly servicing clients in the US."

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.